Abstract Monoamine oxidase (MAO) A and MAO B are a crucial pair of isoenzymes, which oxidatively deaminate monoamine neurotransmitters and dietary amines with a production of hydrogen peroxide. These two isoenzymes have different but overlapping substrate and inhibitor specificities. MAO A and MAO B share 70% amino acid sequence identity and show different temporal and spatial expressions in both humans and mice. Abnormal MAO A or MAO B activity has been implicated in numerous neurological and psychiatric disorders. A better understanding of the transcriptional regulation of MAO A and MAO B genes may help explain the differential tissue-specific expression of these two isoenzymes and provide insights into the molecular basis of the disorders associated with MAO dysfunction. This review discusses the recent progress in the transcriptional regulation and multiple functions of MAO A and MAO B genes.
Introduction
Monoamine oxidase (MAO) [amine: oxygen oxidoreductase (deaminating) (flavin-containing); MAO; E.C. 1.4.3.4.] oxidatively deaminates a number of biogenic and dietary amines in the brain and peripheral tissues and generates the byproduct hydrogen peroxide. MAO exists in two isoenzymes, MAO A and MAO B, with different but overlapping substrate and inhibitor specificities. MAO A preferentially oxidizes serotonin (5-hydroxytryptamine, 5-HT), norepinephrine (NE) and epinephrine and is irreversibly inhibited by low doses of clorgyline. MAO B preferentially oxidizes phenylethylamine (PEA) and is irreversibly inhibited by low doses of deprenyl (selegiline). Dopamine (DA) and tyramine are common substrates for both MAO A and MAO B (Shih et al. 1999) . The success in cDNA cloning of MAO A and MAO B has demonstrated unequivocally that MAO A and MAO B are made of two different proteins, coded by two genes (Bach et al. 1988) . They have identical exon-intron organization, suggesting that they are derived from the same ancestral gene by duplication (Bach et al. 1988; Grimsby et al. 1991) . They are both located on the X chromosome (Xp11.23) (Lan et al. 1989) . MAO A and MAO B proteins share 70% amino acid sequence identity and are located in the outer membrane of mitochondria. Although MAO A and MAO B are widely co-distributed in the central and peripheral nervous systems, MAO A is predominantly found in catecholaminergic neurons, whereas MAO B is more abundant in serotonergic and histaminergic neurons and glial cells (Shih et al. 1999) .
Abnormal MAO activity has been implicated in a variety of neurological and psychiatric disorders, such as depression and social anxiety . MAO A deficiency caused by a spontaneous mutation in the MAO A gene led to impulsive aggressive behaviors and mild mental retardation in affected males in a Dutch family (Brunner et al. 1993) . Consistent with humans, MAO A knock-out (KO) mice also show aggressive behaviors (Cases et al. 1995; Scott et al. 2008) . Low platelet MAO B activity with the increased levels of PEA is associated with alcoholism and stress-related disorders (Devor et al. 1993; Faraj et al. 1994; Grimsby et al. 1997) . Moreover, MAO B KO mice show behavioral disinhibition and reduced anxiety-like behaviors (Bortolato et al. 2009 ). In addition, MAO B activity is significantly increased in the brain with age in rats (Arai and Kinemuchi 1988) and humans (Fowler et al. 1997) , suggesting that MAO B may play a role in aging process.
MAO inhibitors have long been developed and widely used in clinics for the treatment of many neuropsychiatric and neurodegenerative disorders. MAO A inhibitors have been shown to be effective antidepressant drugs . Recent evidence shows that MAO A inhibitors, such as moclobemide, also have antiparkinsonian effects by improving motor function (Sieradzan et al. 1995; Youdim and Riederer 2004) . MAO B inhibitors, such as selegiline (deprenyl) and rasagiline (Azilect Ò , N-propargyl-1-(R)-aminoindan), have been effectively used for the treatment of Parkinson's disease (PD), and their neuroprotective mechanisms have been substantially studied over the past decades (Foley et al. 2000; Mandel et al. 2003) . These inhibitors protect neurons by preventing cell damage from neurotoxins Wu et al. 1995) , free radical formation Chiueh et al. 1992 ) and apoptosis Weinreb et al. 2004) as well as stimulating the expression of neurotrophic factors (e. g. NGF, BDNF and GDNF) (Mizuta et al. 2000; Weinreb et al. 2004) . Recently, structure-activity studies provide evidence indicating the important association of neuroprotection with the intrinsic pharmacological action of the propargylamine moiety in MAO B inhibitors (e.g. rasagiline), which leads to the development of multifunctional chimeric propargylamine-derivatives, such as M30 (BarAm et al. 2005; Zheng et al. 2005; Youdim 2006 ). M30, an ironchelator, possesses the same neuroprotective propargylamine moiety as rasagiline but is a brain selective MAO A and MAO B inhibitor, which shows no cheese effect in response to tyramine, an unwanted side effect associated with earlier inhibitors (Gal et al. 2005 (Gal et al. , 2010a . In addition, these propargylamine-derivative compounds regulate the processing of amyloid-b protein precursor by the nonamyloidogenic a-secretase pathway (Avramovich-Tirosh et al. 2007a, b; Bar-Am et al. 2010) , suggesting the potential use in Alzheimer's disease. Undoubtedly, the studies on the development and the molecular mechanisms of MAO inhibitors not only provided the basis for the clinical treatment of neuropsychiatric and neurodegenerative disorders, but also demonstrated the important role of MAO in the brain.
The transcriptional regulation of MAO A and MAO B genes has been extensively studied in recent years after both MAO A and MAO B genes were cloned (Bach et al. 1988) . Using a series of 5 0 -flanking sequences linked to a human growth hormone receptor gene, we identified the maximum promoter activities for MAO A and MAO B in a 0.14-kb PvuII/DraII and 0.15-kb PstI/NaeI fragment, respectively. Both fragments are GC-rich, contain potential Sp1-binding sites and share approximately 60% sequence identity (Zhu et al. 1992 ). Sp1 and Sp4 trans-activate MAO A and MAO B promoter activities by directly interacting with Sp1 sites, whereas this activation can be repressed by Sp3 and a related family member BTEB2 via the competition for binding to Sp1 sites (Wong et al. 2001; Zhu et al. 1994) . However, the organization of transcription factor binding elements is different between the two promoters. The MAO A 0.14-kb promoter lacks a TATA box, consists of four Sp1-binding sites and exhibits bi-directional promoter activity (Zhu et al. 1994) . The MAO B 0.15-kb promoter consists of two clusters of overlapping Sp1-bindng sites separated by a CACCC element (Ou et al. 2004 ). Moreover, a 30-bp variable number tandem repeat (VNTR) polymorphism is found 1.2 kb upstream of the MAO A coding sequences in human MAO A promoter (Zhu and Shih 1997) . This 30-bp VNTR is present in 3, 3.5, 4 or 5 copies in different individuals across ethnic groups. The polymorphism has been associated with MAO A promoter/enzymatic activity, and alleles with 3.5 or 4 copies of the repeat are more efficiently transcribed than those with 3 or 5 copies of the repeat (Sabol et al. 1998) . The different promoter organization of MAO A and MAO B genes may underline their different tissue-and cell-specific expressions.
Regulation of MAO B gene by TIEG2
The CACCC element flanked by two clusters of overlapping Sp1 sites in MAO B promoter was demonstrated to be a repressor element. The basal MAO B promoter activity increases by eightfold when this element is mutated. Moreover, transforming growth factor-b-inducible early gene (TIEG) 2 exhibits dual functions at the MAO B promoter. TIEG2 acts as a repressor at the CACCC element but an activator at the distal Sp1 sites of MAO B promoter. TIEG2 is capable of directly interacting with the CACCC element and distal Sp1 sites both in vitro and in vivo. Since TIEG2 has a higher affinity to the Sp1 sites than CACCC element, TIEG2 exerts an overall activating effect on MAO B promoter activity and mRNA level (Ou et al. 2004) .
Recently, we and our collaborators have demonstrated that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and MAO B play a contributory role in alcoholism associated with ethanol-induced brain cell damage, which is mediated by the up-regulation of MAO B by TIEG2. Ethanol significantly increases the levels of nuclear GAP-DH and MAO B in neuronal cells as well as in human and rat brains. Moreover, nuclear GAPDH interacts with TIEG2 and further augments TIEG2-mediated MAO B trans-activation, which results in cell damage, correlating with increased levels of hydrogen peroxide, when exposed to ethanol (Ou et al. 2009 (Ou et al. , 2010 . These studies suggest that the interference with TIEG2-MAO B interaction could be an alternative approach in addition to the MAO B inhibitors for treating neuropsychiatric symptoms associated with alcoholism.
Identification of a novel transcriptional repressor R1 (RAM2/CDCA7L/JPO2) for MAO A gene
To search for additional novel transcription factors, which may interact with Sp1 sites and regulate MAO promoters, we used three copies of Sp1-binding motifs derived from MAO B core promoter as bait to screen a human cDNA library in the yeast one-hybrid system. Two novel transcription factors have been identified, one of which was named R1 (RAM2/CDCA7L/JPO2) by us. The other one is currently under investigation.
The R1 cDNA encodes a protein with 454 amino acids, and the C-terminal of R1 protein encompassing 77 amino acid residues (349-425) shows 87% identity with c-Myc targeting protein JPO1, which ultimately leads to tumorigenesis (Chen et al. 2005; Huang et al. 2005) . Further analysis of this region reveals 12 conserved cysteine residues and 4 CXXC zinc finger putative DNA-binding domains, which provides bases for proper protein confirmation for DNA binding. This region is highly conserved between human and mouse R1 with 94% sequence identity. Moreover, a nuclear targeting sequence (amino acids 301-318) and multiple potential phosphorylation sites have been identified, suggesting the cellular location of R1 may be dependent on its phosphorylation level. Similar to MAO genes, R1 is widely expressed in the human brain and peripheral tissues. At the cellular level, R1 is found in both the nucleus and cytosol (Chen et al. 2005) . Our studies and that of other groups have further shown that R1 is a c-Myc interacting protein that potentiates and complements c-Myc transforming activity (Huang et al. 2005; Ou et al. 2006b) .
Subsequent experiments showed that R1 acts as a transcriptional repressor of MAO A gene and represses MAO A promoter activity by competing with Sp1 for binding to Sp1 sites. R1 is capable of directly interacting with Sp1 sites under both in vitro and in vivo conditions. Moreover, over-expression of R1 in stable neuronal cell lines downregulates MAO A enzymatic activity, suggesting its physiological effect (Chen et al. 2005) . Given the multiple functions of R1 in certain cellular events, such as cell proliferation, the possible indirect mechanisms, i. e. other than direct transcriptional regulation, by which R1 regulates MAO A gene, remain to be studied. The regulatory effect/mechanism of R1 on MAO B gene is currently under investigation as well.
Regulation of X-located MAO A gene by sex-determining region gene on the Y chromosome (SRY)
The fact that MAO is located on the X chromosome has driven us to hypothesize whether there is a sex-specific transcription factor regulating MAO gene expression, which provides us bases to speculate the sex dimorphism as observed in several neuropsychiatric disorders associated with abnormal MAO activity, such as depression (Dulcan 1997; Williams et al. 2008; Wright et al. 2009 ) and autism (Williams et al. 2008) . Recently, we and our collaborators have identified MAO A as a novel neural target for the SRY gene in a genome-wide ChIP and promoter tiling microarray analysis. The SRY gene, encoding a putative transcription factor, is the master switch regulator responsible for initiating the testis determination and differentiation during embryogenesis (Wilhelm et al. 2007 ).
SRY activates both MAO A promoter and enzymatic activities via a functional SRY-binding site (-117/-111, AT-rich) in the MAO A core promoter. Sp1 synergistically enhances the SRY activation of MAO A promoter in a dose-dependent manner. Moreover, Sp1 interacts and forms a transcriptional regulatory complex with SRY at the natural MAO A core promoter, which potentiates SRY binding to MAO A promoter (Wu et al. 2009a) . This is the first study showing that the Y-encoded transcription factor SRY is capable of regulating an X-located gene, suggesting a novel molecular mechanism for sexual dimorphism in neural development, brain functions and initiation/progression of neural disorders associated with MAO A dysfunction.
Previous studies have demonstrated that various cofactors interact with SRY to form transcriptional complex that regulate SRY target genes (Li et al. 2006; Oh et al. 2005) . Since other factors, such as Sp3, Sp4 and R1, also utilize the same Sp1 sites, neighboring the SRY site, in their transcriptional regulation of MAO A, it would be interesting to determine whether these MAO A regulators could also interact with SRY, thereby exerting potentially complex transcriptional interplay and sexually dimorphic physiological effects (Fig. 1) . Moreover, recent studies have suggested that some neuropsychiatric disorders, such as autism, may originate in early embryonic development (Ploeger et al. 2010) . Hence, understanding how the transcriptional network coordinated by SRY or other sexdetermining factors regulates MAO A gene during brain development may provide insights into addressing the role of MAO genes in these mental disorders which show sexual dimorphism and MAO dysfunction. These studies are currently under investigation.
Regulation of MAO genes by methylation
Several lines of direct and indirect evidence suggest DNA methylation can be a factor/mechanism contributing to the regulation of MAO genes. For example, variations of MAO activity have been associated with their methylation status of promoters in smoking groups (Launay et al. 2009 ). The most direct evidence is the identification of functional CpG islands (CGIs) in the MAO promoters. There is a putative CGI containing 22 potential CpG methylation sites in the MAO B promoter (-261/-58). In vitro demethylation of MAO B promoter with 5-aza-2 0 -deoxycytidine, a DNA methyltransferase inhibitor, up-regulates MAO B gene expression in both HeLa and Caco-2 cells (Wong et al. 2003) . Since the CGI in the MAO B promoter encompasses several Sp1 sites (GC-rich), the lower MAO B promoter activity under methylation status could also be likely due to its altered chromatin structure, which impedes the recruitment of transcription factors, such as Sp1, to this region.
Recently, other groups report that the extended MAO A regulatory region contains two CGIs, one of which overlaps with the canonical MAO A promoter and the other is located further upstream. Both CGIs exhibit sensitivity to differential methylation (Shumay and Fowler 2010) . Moreover, the effect of VNTR on the MAO A transcription may have epigenetic nature, as this polymorphic region resides within the CGI of MAO A promoter and itself contains CpG sites. Thus, the number of repeats, correlating with the number of methylatable cytosines in the MAO A promoter, could exert a possible effect on the transcriptional activity of MAO A.
Hormonal regulation of MAO A and MAO B genes
Emerging evidence has shown that steroid and non-steroid hormones are involved in the regulation of many neuropsychiatric processes in which MAO also plays a critical role, such as responses to stress, behavioral adaption and mood (de Kloet et al. 1990 ). For instance, significant hypersecretion of glucocorticoids has been shown to be associated with depression (Duval et al. 2006) , and antiglucocorticoid agents have been used in the treatment of depression (Wolkowitz and Reus 1999) . We have been dedicated to investigating the hormonal regulation of MAO genes and the corresponding mechanisms at the molecular level in recent years. To date, we have demonstrated that androgen, glucocorticoid (Ou et al. 2006a ) and retinoic acid (RA) (Wu et al. 2009b ) activate both MAO A and MAO B gene expression albeit to different extents in human neuronal cell models, whereas estrogen shows tissue-specific effect on MAO A and MAO B genes (Holschneider et al. 1998) . Since these hormones play a pivotal role(s) in many physiological and pathological states, our findings may thus Fig. 1 A schematic diagram of the 2-kb promoter organization, transcriptional regulation and regulatory effects of MAO genes. The size is not proportional to the promoter structure also provide insights into the potential new functions of MAO genes in these hormone-controlled steps/processes.
Androgen and glucocorticoid
Androgen and glucocorticoid show their capabilities to upregulate MAO A gene in a canonical way by directing their receptors to bind to a functional androgen/glucocorticoid response element (-289/-275) in the MAO A promoter. On the other hand, both androgen and glucocorticoid receptors interact with Sp1 sites indirectly via Sp1, and such interaction is enhanced in response to ligands. Moreover, glucocortcoid but not androgen induces R1 translocation. R1 is translated into the nucleus upon 12-h dexamethasone (a synthetic glucocorticoid) and re-located into the cytosol after 24-or 48-h treatment (Ou et al. 2006a ).
Retinoic acid
Similarly, RA activates the MAO B transcription by both ligand-receptor interaction and crosstalk between the receptor and transcription factor Sp1 as well. Retinoic acid receptor a (RAR a), but not retinod X receptor a, binds to a functional RA response element (-303/-287) in the MAO B promoter. Mutation of Sp1 sites or interference of Sp1-binding ability down-regulates the RA activation of MAO B promoter, suggesting a mediating role of Sp1 in this activation. Further analysis shows that RAR a interacts with Sp1 via the zinc finger domains in Sp1. Furthermore, RAR a is able to be recruited by Sp1 and forms a transcriptional regulation complex with Sp1 at the Sp1 sites in the MAO B promoter in vivo, which enhances Sp1-binding ability (Wu et al. 2009b ).
Estrogen
The interplay of estrogen receptors (ERs) and estrogenrelated receptors (ERRs) in the regulation of MAO B promoter activity has been studied in breast cancer cells. ERR a recognizes a variety of estrogen response elements (EREs) and shares many target genes and cofactors with ER a. ERR a and ERRT up-regulate MAO B gene expression, whereas this up-regulation is repressed by ER a and ER b in both ligand-dependent and -independent manners. In contrast to ER-negative HeLa cells, the ability of ERRs to stimulate MAO B promoter activity is reduced in ER-positive MCF-7 and T47D cells. Several EREs responsible for the up-regulation by ERRs are located in the MAO B promoter, and ERs compete with ERRs for binding to the MAO B promoter at selective ERR motifs (-1,762, -1,468, and -289/-286) , thereby changing the chromatin status and cofactor recruitment to a repressed state (Zhang et al. 2006) .
MAO genes in apoptosis and stem cell proliferation MAO A has long been suggested as a pro-apoptotic gene. MAO A expression increases during the apoptosis induced by the withdrawal of neurotrophic factors in PC12 cells, which is mediated via p38 kinase pathway (De Zutter and Davis 2001) . Moreover, clogyline, a MAO A inhibitor, shows protective effects from serum starvation-induced apoptosis in human melanoma M14 cells (Malorni et al. 1998) . Recently, the roles of MAO A and its novel transcriptional repressor R1 in apoptosis and cell proliferation are further studied in a human neuronal cell model and MAO A KO mice. In response to serum starvation, the expression of p38, MAO A and caspase-3 increases, whereas Bcl-2 and R1 levels decrease. MAO A and R1 are demonstrated downstream of p38 kinase and Bcl-2 but upstream of caspase-3. Consistently, the serum starvationinduced apoptosis is reduced in cortical brain cells from MAO A-deficient mice in comparison with the wild-type control. Furthermore, cyclin D1 and E2F show negative correlation with MAO A in an R1-modulated manner and act as downstream targets of MAO A-and R1-mediated cellular proliferative pathway (Ou et al. 2006b ).
In contrast to MAO A, MAO B is induced by phorbol-12-myristate 13-acetate (PMA), a tumor-promoting agent, which is mediated via the activation of PKC and MAPK signaling pathways. Further studies show that transcription factor Egr-1 and c-Jun are ultimately responsible for the induction of MAO B gene by directly interacting with the overlapping Sp1/Egr-1/Sp1-binding sites (-246/-225) in MAO B core promoter (Wong et al. 2002) . Since PMA has shown to stimulate cell proliferation in a number of cell models (Amos et al. 2005; Isakov et al. 1993) , this regulation may suggest a potential role of MAO B in regulating cell proliferation.
One possible mechanism by which MAO genes influence cell proliferation is via the control of specific neurotransmitter levels, such as serotonin. Numerous studies have well documented the role of serotonin along with its receptors in stimulating cell proliferation and tumor growth in an array of cancer cell models, such as prostate and hepatocellular carcinomas (Siddiqui et al. 2006; Soll et al. 2010) . Moreover, our recent study shows that mice lacking both MAO A and MAO B (MAO AB double KO) exhibit diminished proliferation of neural stem cells in late embryonic and early postnatal development, which is mediated by serotonin (Cheng et al. 2010) . It would be interesting to study the transcriptional regulatory patterns of MAO genes during embryonic and early postnatal developmental stages, which may provide new clues for understanding the profound changes in cell proliferation capacity caused by altered neurotransmitter levels.
Summary and future prospective
The current knowledge on the promoter organization and transcriptional regulation of MAO A and MAO B genes has been reviewed here. The Sp1-binding sites and Sp-family/Sp-family-like transcription factors were identified to be the major players for regulating both MAO A and MAO B promoters. On the other hand, MAO A and MAO B also show differential regulatory mechanisms in terms of their responses to different transcription factors, cellular signal transductions and hormones. For example, MAO A is up-regulated by SRY, whereas MAO B shows the induced responses to TIEG2. In contrast to MAO A, which is involved in a c-Myc-and R1-mediated apoptotic signaling pathway, MAO B is activated by PKC and MAPK cascades. Moreover, MAO A and MAO B are distinctly regulated by diverse hormones in terms of their extent of responses in different cell models and tissue regions. These differential regulations may contribute to the differences in the temporal/spatial expression and physiological functions between these two isoenzymes. In addition, the identification of novel/unique transcription factors of MAO genes (e.g. R1, a c-Myc interacting protein which enhances c-Myc transforming activity) may provide insights into the new functions of MAO genes (e.g. a potential role in tumor progression) as well as the molecular basis of neuropsychiatric disorders associated with MAO dysfunction. Modulation of endogenous levels of such factors could be considered as an alternative approach to maintain normal MAO activity in addition to using MAO inhibitors. The translational values of these findings will be further investigated.
